Infarmed Datroway Funding Rejection for HR+ Breast Cancer

The Infarmed Datroway Funding Rejection blocks public funding for this drug because the public assessment report finds no proof of added therapeutic value. Although Datroway was compared with paclitaxel, vinorelbine, capecitabine, carboplatin, gemcitabine or talazoparib, the TROPION-Breast01 trial showed better progression-free survival without any overall-survival benefit, and quality of life along with other endpoints also failed to demonstrate superiority, so Infarmed rejected funding for HR-positive, HER2-negative unresectable or metastatic breast cancer.

Key Insights

The report lists several key results from the pivotal trial. Progression-free survival reached statistical significance with an HR of 0.63, while overall survival showed no difference with an HR of 1.01. Objective response rate favoured Datroway, yet quality-of-life data remained mixed and evidence quality was moderate for survival endpoints but very low for quality of life and safety. The added benefit was rated not proven on every endpoint, even though safety data showed lower rates of grade 3 or higher adverse events alongside higher stomatitis and ocular toxicity.

• Progression-free survival: HR 0.63
• Overall survival: HR 1.01
• Study size: 732 patients
• Median progression-free survival: 6.9 months versus 4.9 months
• Objective response rate: 36.01% versus 21.58%
• Duration of response: 6.7 months versus 5.7 months
• Median overall survival: 18.6 months versus 18.3 months (not statistically significant)
• Grade 3 or higher adverse events: 32.5% versus 54.1%

Background Context

The assessment followed Decreto-Lei n.º 97/2015 and Decreto-Lei n.º 118/2016 and targeted adults with HR-positive, HER2-negative unresectable or metastatic breast cancer who had received prior endocrine therapy plus at least one chemotherapy line. This subtype accounts for roughly 70% of advanced breast cancers in Portugal, and the evidence came from the TROPION-Breast01 phase III trial that compared Datroway with investigator-choice chemotherapy. Limitations included heavy use of unfunded eribulin in the control arm, exclusion of anthracyclines and taxanes from that arm, and differing later use of other antibody-drug conjugates, all of which are discussed in the full Infarmed public assessment report.

Ad

Implications

Health economics models must now rely only on progression-free survival gains because no overall-survival or quality-of-life gains can be assumed. Payers may request new head-to-head trials against funded regimens, and real-world evidence could help define the drug’s place in sequences. The Infarmed Datroway Funding Rejection highlights the need to match trial control arms with national reimbursed options, so future economic evaluations will face stricter scrutiny on applicability.

FAQ

What is the funding decision for Datroway?

Infarmed rejected funding. The medicine showed no added therapeutic value over existing systemic treatments.

Did the TROPION-Breast01 study show an overall-survival benefit?

No. The final analysis found no statistically significant overall-survival difference.

Which safety concerns were more frequent with Datroway?

Mucositis, stomatitis and ocular surface toxicity occurred more often with Datroway. Overall grade 3 or higher adverse events were lower than with chemotherapy.